<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="ijms-21-05145-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">ijms-21-05145-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>Present Coronavirus (CoV) drug treatment options.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment (Therapeutics Class)</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target/Mechanism</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="15" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Small molecules inhibitors</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Helicase</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Patents [
     <xref rid="B50-ijms-21-05145" ref-type="bibr">50</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">KR20100029528A; 2010</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KR20110006083A; 2011</td>
   </tr>
   <tr>
    <td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Proteases</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Patents [
     <xref rid="B50-ijms-21-05145" ref-type="bibr">50</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">KR20100066142A; 2010</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">CN101418334A; 2009</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">CN101701245A;2010</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">CN101921823A; 2010</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KR20110068191A; 2011</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Host cell proteases</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B16-ijms-21-05145" ref-type="bibr">16</xref>,
     <xref rid="B18-ijms-21-05145" ref-type="bibr">18</xref>,
     <xref rid="B50-ijms-21-05145" ref-type="bibr">50</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Host cell endocytosis</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B16-ijms-21-05145" ref-type="bibr">16</xref>,
     <xref rid="B18-ijms-21-05145" ref-type="bibr">18</xref>,
     <xref rid="B50-ijms-21-05145" ref-type="bibr">50</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S-protein/Inhibition of SARS-CoV fusion and entry into the host cell</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B49-ijms-21-05145" ref-type="bibr">49</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S cleavage/Inhibition of functional S1 and S2 subunits production</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B49-ijms-21-05145" ref-type="bibr">49</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD-ACE2/Blocking
     <break/>S-protein-mediated infection
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B49-ijms-21-05145" ref-type="bibr">49</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA synthesis inhibitors (3TC, TDF)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B18-ijms-21-05145" ref-type="bibr">18</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Renin-angiotensin system (RAS) inhibitors</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACE1 and Angiotensin type 1 receptors</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B54-ijms-21-05145" ref-type="bibr">54</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Antisense RNA (siRNA)</td>
    <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduction of virus replication and/or silencing of S gene expression</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">[
     <xref rid="B49-ijms-21-05145" ref-type="bibr">49</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Patents [
     <xref rid="B50-ijms-21-05145" ref-type="bibr">50</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CN101173275; 2008</td>
   </tr>
   <tr>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ribozyme</td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cleavage of coronavirus gene</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Patents [
     <xref rid="B50-ijms-21-05145" ref-type="bibr">50</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US2010273997A1;2010</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutralizing antibodies</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spike glycoprotein/Inhibit SARS-CoV fusion and entry into the host cell</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B16-ijms-21-05145" ref-type="bibr">16</xref>,
     <xref rid="B49-ijms-21-05145" ref-type="bibr">49</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IVIgG and LMWH (low molecular weight heparin) anticoagulant therapy</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of biological activity/viral replication</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B14-ijms-21-05145" ref-type="bibr">14</xref>,
     <xref rid="B16-ijms-21-05145" ref-type="bibr">16</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mAbs</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Full-length S-protein orS1-receptor-binding domain (RBD)/Inhibition of SARS-CoV fusion and entry into the host cell</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B16-ijms-21-05145" ref-type="bibr">16</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral peptides acting on S2</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of production of functional S2</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B16-ijms-21-05145" ref-type="bibr">16</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">Remdesivir (Nucleoside analogues)</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">RdRp/Terminates the non-obligate chain</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">[
     <xref rid="B45-ijms-21-05145" ref-type="bibr">45</xref>,
     <xref rid="B52-ijms-21-05145" ref-type="bibr">52</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Lopinavir/Ritonavir/ASC09F/
     <break/>Darunavir/Cobicistat
    </td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">3CLpro/Protease inhibitors</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[
     <xref rid="B52-ijms-21-05145" ref-type="bibr">52</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Oseltamivir</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Neuraminidase inhibitors</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[
     <xref rid="B50-ijms-21-05145" ref-type="bibr">50</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Peptide EK1</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Spike glycoprotein/Inhibits pan-CoV fusion</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[
     <xref rid="B50-ijms-21-05145" ref-type="bibr">50</xref>,
     <xref rid="B76-ijms-21-05145" ref-type="bibr">76</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Arbidol (Antiviral)</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Effect on several stages of the viral life cycle, such as cell entry (attachment, internalization) and replication</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[
     <xref rid="B16-ijms-21-05145" ref-type="bibr">16</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Association Lopinavir/Ritonavir/Ribavirin/
     <break/>IFN beta1b
    </td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">SARS anti-CoV2 activity</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[
     <xref rid="B60-ijms-21-05145" ref-type="bibr">60</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Association
     <break/>IFN alpha2b/Umifenovir
    </td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">SARS anti-CoV2 activity</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[
     <xref rid="B61-ijms-21-05145" ref-type="bibr">61</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Association IFN beta1a hydroxychloroquine Lopinavir/Ritonavir</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">SARS anti-CoV2 activity</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[
     <xref rid="B62-ijms-21-05145" ref-type="bibr">62</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Chloroquine and hydroxychloroquine</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Endosomal acidification/Acting on a lysosomotropic base that appears to disrupt intracellulartrafficking and viral fusion events</td>
    <td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[
     <xref rid="B64-ijms-21-05145" ref-type="bibr">64</xref>,
     <xref rid="B70-ijms-21-05145" ref-type="bibr">70</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Teicoplanin
     <break/>(glycopeptide antibiotic)
    </td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Blocked virus entry by specifically inhibiting the activity of cathepsin L</td>
    <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B72-ijms-21-05145" ref-type="bibr">72</xref>,
     <xref rid="B75-ijms-21-05145" ref-type="bibr">75</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tocilizumab (recombinant humanized anti-human IL-6 receptor monoclonal antibody)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-6 blocker</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B57-ijms-21-05145" ref-type="bibr">57</xref>,
     <xref rid="B58-ijms-21-05145" ref-type="bibr">58</xref>]
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
